Cardinal Health
30-Second Executive Brief
Executive Assessment
Cardinal Health functions as an established institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, with accelerating strategic relevance.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Major US pharmaceutical and medical products distributor; reported fiscal year 2026 (ended June 2026) revenues of $254.2 billion (up 14% year-over-year) with non-GAAP diluted EPS up 37% to $11.26, and guided fiscal year 2027 non-GAAP diluted EPS of $12.40-12.60, representing 13-15% growth.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Defense — $11,049,212: 4570333097!OCP, JFAK COMPLETE, NSN 6545-01-632-0167
USAspending.gov · Dec 19, 2025
Department of Veterans Affairs — $3,004,754: RADIOPHARMACEUTICALS
USAspending.gov · Oct 1, 2025
Department of Defense — $2,818,257: 8510084616!SUPPLYLINE MASTER AGREEMENT
USAspending.gov · Sep 20, 2023
Department of Veterans Affairs — $2,717,102: RADIOPHARMACEUTICALS NF/SG VHS FY25 10-01-2024 TO 09-30-2025
USAspending.gov · Oct 1, 2024
Department of Veterans Affairs — $2,715,757: RADIOPHARMACEUTICALS
USAspending.gov · Oct 1, 2022
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- RTTNews — Cardinal Health Delivers Double-Digit FY2026 Earnings Growth; Sets Strong FY2027 Outlooknews
Latest Activity
- FilingCardinal Health filed an 8-K (items 1.01,1.02,2.03,9.01)8-K
- FilingCardinal Health filed an 8-K (items 2.02,7.01,9.01)8-K
- FilingCardinal Health filed an 8-K (items 5.02)8-K
- FilingCardinal Health insider selling — $546,473 saleForm 4
- FilingCardinal Health insider selling — $6,998,424 saleForm 4
- FilingCardinal Health insider selling — $1,731,524 saleForm 4
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Cardinal Health — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Cardinal Health's Timeline
A sourced, dated history of Cardinal Health's key moments — founding to present.
Aug 2026 · FY2026 revenue rises 14% to $254.2 billion; sets strong FY2027 outlook
Cardinal Health reported FY2026 revenues of $254.2 billion, up 14% year-over-year, with non-GAAP operating earnings up 30% to $3.624 billion and non-GAAP diluted EPS up 37% to $11.26; the company guided FY2027 non-GAAP diluted EPS of $12.40-12.60, representing 13-15% growth.